Delivered-To: pgepnewsletter@gmail.com
Received: by 2002:a05:640c:3013:b0:1ee:4bd3:5fc9 with SMTP id z19csp198182eiw;
        Sat, 20 Jan 2024 10:32:16 -0800 (PST)
X-Google-Smtp-Source: AGHT+IHLeCx+ceuTYzhUD87Kd4TEzx4LBWA41I1IzzNjH7bTirkYRWL0VHw+a2qnn3MTPEL5lqIm
X-Received: by 2002:a05:6808:ec6:b0:3bd:4c75:e0ab with SMTP id q6-20020a0568080ec600b003bd4c75e0abmr2165373oiv.48.1705775535888;
        Sat, 20 Jan 2024 10:32:15 -0800 (PST)
ARC-Seal: i=1; a=rsa-sha256; t=1705775535; cv=none;
        d=google.com; s=arc-20160816;
        b=01oeLlhzBGEJE5ctTkV3NAuBCegc9DRySbpqNWaDkcMWBxOMPUgnK+rIhCODz9iDiZ
         6GCNwSij7GoA6RuZmXVvZqWE7u/7nyWY0uoqftIuEAVl0Yprb7RYFSwbjkdsPyE00GWg
         wv/HFQYsKiCzGP6lleyxiRWMDKmrkvYWQkQtvvD6rHJg2ubZTQS4sAqxfMKil42oKBCq
         4G/bNjqDIVga1vAJ7YxuapKyZuXjMD51EANtz5e9LUbaq7E5I+wdqKwUsgfg2ww9oix0
         t6OvPrlPfCBX3qR7GNn7Zb8QIXHGZmoOVKxbnbIsQ6vhWiDb4+j1C7wOGpGJfmz/Klhg
         X24g==
ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20160816;
        h=list-unsubscribe:to:reply-to:subject:message-id:mime-version:from
         :date:dkim-signature:dkim-signature;
        bh=lVq5S+kBaNpoIM03m3NR8ASH7vLZ1idmCdEJjMyD7G4=;
        fh=m8+yFGL9AGrkSifADXzxzWHypeMVd9MF7/kbikeN2H4=;
        b=BSLNdh0/aM+soBHu+N6THw+GICT0AqEGA6B/j77IsCCj9fs2FEHnYvC8oOkZF19xLp
         X99r3Udg/wFhzqeENp8juaqmrmBzfzvXkPDZF8QVApnQdG2lQaKzGoVphn1U7GWpJH3s
         ZxVTPZEyeaK2U8kzPZgz3i9zJ0Ovihv6qKVX//lpOw41vXdFo92g5IbgkDtDr6Km6s/2
         IJNx1ixUrdPXgwkZ1DQf+XvI+i71eqCBoyCafMusOYU/hNAnpRb+gm+RgP374rhlyIo7
         NwjCiXFTikk+whaKzzY9J1rqePif8f4L6kBxHjorsv4vRF7Bb3DwRutMs0EKmxEp0jym
         V+Tg==
ARC-Authentication-Results: i=1; mx.google.com;
       dkim=pass header.i=@isid.org header.s=s1 header.b=ZvEsrjIv;
       dkim=pass header.i=@sendgrid.info header.s=smtpapi header.b=dACpfIdA;
       spf=pass (google.com: domain of bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org designates 167.89.81.226 as permitted sender) smtp.mailfrom="bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org";
       dmarc=pass (p=NONE sp=NONE dis=NONE) header.from=isid.org
Return-Path: <bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org>
Received: from xtrwrkzn.outbound-mail.sendgrid.net (xtrwrkzn.outbound-mail.sendgrid.net. [167.89.81.226])
        by mx.google.com with ESMTPS id l21-20020a05622a175500b0042a3548558csi685400qtk.617.2024.01.20.10.32.15
        for <pgepnewsletter@gmail.com>
        (version=TLS1_3 cipher=TLS_AES_128_GCM_SHA256 bits=128/128);
        Sat, 20 Jan 2024 10:32:15 -0800 (PST)
Received-SPF: pass (google.com: domain of bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org designates 167.89.81.226 as permitted sender) client-ip=167.89.81.226;
Authentication-Results: mx.google.com;
       dkim=pass header.i=@isid.org header.s=s1 header.b=ZvEsrjIv;
       dkim=pass header.i=@sendgrid.info header.s=smtpapi header.b=dACpfIdA;
       spf=pass (google.com: domain of bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org designates 167.89.81.226 as permitted sender) smtp.mailfrom="bounces+19268662-547c-pgepnewsletter=gmail.com@em7004.isid.org";
       dmarc=pass (p=NONE sp=NONE dis=NONE) header.from=isid.org
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=isid.org;
	h=content-type:from:mime-version:subject:reply-to:x-feedback-id:to:
	list-unsubscribe:cc:content-type:from:subject:to;
	s=s1; bh=lVq5S+kBaNpoIM03m3NR8ASH7vLZ1idmCdEJjMyD7G4=;
	b=ZvEsrjIvqkAAulxaV1wC7J2pqh2/vBwXgChf7Ashb0pgfTLTpWR/r529nD+u0URh3l3K
	0t8wexrh26/JUGwOiE08Fi83vMwSvCRCjmzbPng9CauGFsPcOeoC+GqsXKc3E0cITLIDml
	dXCanQ2CcKMjiiqUkNISUN8wepucMpWVukCuIqj7iGY93dqhh+1shpBugpzWhxpUox0WGR
	435piAMOdkwQgM6ztcj+FKAeHAz1hzKshVpIHZXOznuf8ee2Ce+AHtkszOW8okaRq5/bCK
	lJeNDyMi50XKnOhaSWrddJo4V74LAAPqCwvwpgRSbNdbIEwumVWZJIkn4p2ZlQ2w==
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=sendgrid.info;
	h=content-type:from:mime-version:subject:reply-to:x-feedback-id:to:
	list-unsubscribe:cc:content-type:from:subject:to;
	s=smtpapi; bh=lVq5S+kBaNpoIM03m3NR8ASH7vLZ1idmCdEJjMyD7G4=;
	b=dACpfIdAiq9aNhnX13Wxj8X720qsoAlHuFwBRAyg7yHwxbQqIBYg9UM36WQqriZQH9kg
	iuzfhAHUgxWYIcXhkzL9/b/R/unwNL2xh2lIveH0Sb7OlsP1LODW5TLoo2gjfHKuz8cB7I
	HS+j5i1d8rfhfnwFV/JykfMEkAlhhkkxQ=
Received: by filterdrecv-5579bc58-4nbx9 with SMTP id filterdrecv-5579bc58-4nbx9-1-65AC11AC-8B
        2024-01-20 18:32:12.857847755 +0000 UTC m=+8207449.145335150
Received: from MTkyNjg2NjI (unknown)
	by geopod-ismtpd-35 (SG) with HTTP
	id BhLuB-bdRJe80kBhXFMHtA
	Sat, 20 Jan 2024 18:32:12.666 +0000 (UTC)
Content-Type: multipart/alternative; boundary=4e9324041eb89adb31d09602fbe3252c288b88fbd9a6defb07d4bdf3efb3
Date: Sat, 20 Jan 2024 18:32:14 +0000 (UTC)
From: ProMED <promed@isid.org>
Mime-Version: 1.0
Message-ID: <BhLuB-bdRJe80kBhXFMHtA@geopod-ismtpd-35>
Subject: PRO/AH/EDR> COVID-19 update (07): Bangladesh, JN.1, variant of
 interest
Reply-To: noreply@isid.org
X-Feedback-ID: 19268662:SG
X-SG-EID: 
 =?us-ascii?Q?lYKUi1ucKQwcfoVB1xAcbBSlsJP9QSi7ed2VWI0p5NjpCc5BQK+kujBGGO1mU1?=
 =?us-ascii?Q?iBErhwq2SsGai8Q0W10+FLtBg4cub5ly2axjVFj?=
 =?us-ascii?Q?wJcpUmchmErBWSt7gTPIpnmCrM2UxkPLkMDtaxt?=
 =?us-ascii?Q?wrFUs3txdy5dw4s+8yD=2FMg1n=2FCMZqwGVljb3yj8?=
 =?us-ascii?Q?4A7VNhSeHWnBttQ5C4joG02GmzqYXRN8YW1=2FRty?=
 =?us-ascii?Q?fb+r6kjbyTrfD4hb12zGNkIy64jZjVGt2JCUB9?=
X-SG-ID: 
 =?us-ascii?Q?se=2F49CGmbS0sfR97ImeXvNhg9p9jggtUUChgqoY2wUiShGf=2FO8XJWpH34Od4Nd?=
 =?us-ascii?Q?fxXa6jil96uRcJkF+N+LeVnO1tx80ddOyoyOo=2Fc?=
 =?us-ascii?Q?Brxcl3ERAm0cOY743=2FFH59DWiSf5OzXORh1DLKt?=
 =?us-ascii?Q?hb1NMKty3PsA5ju0ZzxCrq1WQuZSEQf=2FJlWtgqv?=
 =?us-ascii?Q?cZmsyCHlNUZsD+bz5eik+AtEy=2FTVWaozNV9n45I?=
 =?us-ascii?Q?CAgYKyASenqWEGB1VaiSBByt89PAjgscqdKbnpj?=
 =?us-ascii?Q?K30oc63I=2FhEi0lqRWD9WiyBp=2F0SMoDEDdgm1T73?=
 =?us-ascii?Q?gimMTmkchLZHGfXrjWMCJzaY5F4am7DkDcPRSXF?=
 =?us-ascii?Q?InPEPedCUQV4Mtru0mTM0=2Fm4+ciWN8rCkDt2jlF?=
 =?us-ascii?Q?BD8u1INU9D=2F5+SRI2gYccZ5Lb1vGtTB07U5jdFN?=
 =?us-ascii?Q?iVL10EWwTsOaphh2v=2Fpsif2h4u0Jyug+9UarhX0?=
 =?us-ascii?Q?t5FXRRtgQAeCiJGx8Gyabofx+8PKDomSfCeLVR2?=
 =?us-ascii?Q?NDfDS1vhzvxQL+HT9qGNpbeq+W899FxdHmse8wF?=
 =?us-ascii?Q?691mEng=2FmlmHW2KM3Pd9s88ha=2FkPgxIeAT2rx4C?=
 =?us-ascii?Q?DrK5W=2FvBrDtUFEOps3DA+InVAxcFkRPzlRquWDV?=
 =?us-ascii?Q?qLiZfYbHhG6LT6dDjuEvfPkU=2FI8cAejZxeLz=2F5P?=
 =?us-ascii?Q?eouGbQUaEtpyzMTmtWj7r4QmMBCKwo38UzdstPW?=
 =?us-ascii?Q?xstjbIYsXS2vr60DpsPAljP3v8JsPetEyvv1SvB?=
 =?us-ascii?Q?eDVPNDuFrkWwxBWFLpzKGWTGeW+HUSsJkVXzSx8?=
 =?us-ascii?Q?VsHpA+W9L7OV4XRFHuZDW4fAqQ=3D=3D?=
To: pgepnewsletter@gmail.com
X-Entity-ID: 3CKJgmVGbBVD214dsRqreg==
List-Unsubscribe: 
 =?us-ascii?Q?=3Cmailto=3Aunsubscribe=40em7004=2Eisid=2Eorg=3Fsubject=3D19268662=2E6zmn1U17d?=
 =?us-ascii?Q?oHjF9JmrxxzfvT7fQMO7rBtde4XmLyP3vJoMDAw?=
 =?us-ascii?Q?dTAwMNO=5FqGJUFnQ5zrkIuT=5F1WuVvUkGM=5FubrLEF?=
 =?us-ascii?Q?gNi8P8qTXkf8BsGU8vjcTR7GqutgP-sedF3T5RH?=
 =?us-ascii?Q?4RRDw39fNxbUYsb7sfBDV=5FULoFjKFK8Jpmae2-t?=
 =?us-ascii?Q?efsciwMHfL4YSojGA=3D=3D=2EcCyFKXp0rgIUI16CfNC?=
 =?us-ascii?Q?kRwLVepk139Db-5Rwo9YXf5toMDAwdTAwMP86q3?=
 =?us-ascii?Q?kL3v1-Of79284ikh=5FIYnAKJOMEHzpEFw0ByQDND?=
 =?us-ascii?Q?YvEnKJNQvOVHeflbvS-uPjlFkHxW7AONP-eUQoW?=
 =?us-ascii?Q?khfDMke8lhYjlZS2pijz6b=5FXRm1PuCNuwMNEgxS?=
 =?us-ascii?Q?cRt1UuAgdEzuI5nDBVq5orUXQBQ1wWLHYCHbC8l?=
 =?us-ascii?Q?TcMKGt18G08XTlhOxk75GRjMpLtvbYiy32xKnQJ?=
 =?us-ascii?Q?QWNWaB=5FXI5dZd8WW7S0jtaxbEH7GVvxfusPViaq?=
 =?us-ascii?Q?GSiEp9VIRICIzg1Q343ec6hocy-SqfrltWP1Unz?=
 =?us-ascii?Q?zEG6Ag2U1eWxHeGNuKMIftLhU0uhIsVzNfn7BTj?=
 =?us-ascii?Q?i98HLySg4kTbaE=5F1XxJh8B-v6LHN-uox5SvYf8j?=
 =?us-ascii?Q?lM2Xe-ChN4UVBNqOx421erhrP=5FOmYYfSLsX0gIe?=
 =?us-ascii?Q?ehPbF=5FUp8fdX-W1cT-Bbh1umJ1e7saVmnFQKJzz?=
 =?us-ascii?Q?SET1zr4yfwmhetERZnTJTxaUyGlzpgCF69po7lb?=
 =?us-ascii?Q?X3Nz0EDDs-H9rmuMUz8qN9WwJbUN=5FUKSCktb0Ry?=
 =?us-ascii?Q?9vQ9XWivpKMeizc52=5F4=5F3rTqXioRIciP2aQ9ieT?=
 =?us-ascii?Q?lltS8hp0PbrhsnwmSGMMoKXovYHcmXfIRPQUON0?=
 =?us-ascii?Q?uZDW=5FmH-Q8VTTCBhvFXi6bv0mjoZ0DVeaXjPLer?=
 =?us-ascii?Q?p2wMrjQ9oL0yE8dlojMNJ29tvy3XKf-FKBmQtjm?=
 =?us-ascii?Q?LGIHJjykwwGoq64fYNKVPEu=5FL4K1RASgRYahuV4?=
 =?us-ascii?Q?vQPmptFLIyfQORge4kMMSJ0DHtYoOe-Rg9ggP-b?=
 =?us-ascii?Q?gNDLIOgCAHvb-DSACFpcmGUL5GghgqsNy3qxxzm?=
 =?us-ascii?Q?sKT7g0ABg4BcFw2I6CFM876EmEn7oWjgaKAsi2X?=
 =?us-ascii?Q?GJZsdRfYi37JBlIIPCRpUAngYcLgFJILbPyl=5FJG?=
 =?us-ascii?Q?4lzYIw21vvvhaKyMONxLk=5FM9992dLL0C1p8Tg7F?=
 =?us-ascii?Q?=5FZmzHTsWVA53BEmJ3ATbEI5rCjDfRfaIUcd-q=5Fz?=
 =?us-ascii?Q?RGspjZBxfQFyH4taN9VD0s=5F=5FQSWMNU=5FaOWDiinC?=
 =?us-ascii?Q?0AOqpt6WGC0BOPItKhMx758CA-oZ1VZKzIC-6xy?=
 =?us-ascii?Q?exurEQ=3D=3D=3E?=

--4e9324041eb89adb31d09602fbe3252c288b88fbd9a6defb07d4bdf3efb3
Content-Transfer-Encoding: quoted-printable
Content-Type: text/plain; charset=us-ascii
Mime-Version: 1.0

CORONAVIRUS DISEASE 2019 UPDATE (07): BANGLADESH, JN.1, VARIANT OF
INTEREST
***************************************************************************
A ProMED-mail post
<http://www.promedmail.org>
ProMED-mail is a program of the
International Society for Infectious Diseases
<http://www.isid.org>

Date: Thu 18 Jan 2024
Source: The Daily Star [edited]
<https://www.thedailystar.net/health/disease/news/bangladesh-reports-first-=
case-covid-19-sub-variant-jn1-3522486>


Bangladesh has reported its 1st case of COVID-19 sub-variant JN.1,
Institute of Epidemiology, Disease Control and Research (IEDCR) said
today [18 Jan 2024].

This variant has been detected from 5 individuals, but they don't have
any travel history, Professor Tahmina Shireen, director of IEDCR, told
The Daily Star.

She said, "Omicron's sub-variant JN.1 has been identified in 5 samples
testing samples of coronavirus patients from Dhaka and from outside
Dhaka."

--
Communicated by:
ProMED
via
ProMED-SoAs

[As indicated in the news report above, the more infectious JN.1
sub-variant of the omicron variant has been detected in 5 COVID-19
cases in Bangladesh. With this confirmation, Bangladesh has become the
3rd country in South Asia, after India and Pakistan, reporting the
presence of this sub-variant.

Recently, a slight up-trend of the COVID-19 cases is being reported in
Bangladesh
(<https://www.thedailystar.net/health/disease/coronavirus/news/covid-positi=
vity-rate-rises-upto-45pc-3510936>).
Around 5 weeks back, the start of a similar up-rise trend of daily
cases had cautiously been observed across India, suspected to have
been attributed to the spread of the sub-variant JN.1. The daily
reported cases are now decreasing again in the country (see archive
no. http://promedmail.org/post/20240117.8714266). Anyway, the spread
of the sub-variant in Bangladesh should be closely monitored until the
recently noticed temporal surge dies completely.

Of note, "JN.1 is closely related to the variant BA.2.86.... It is not
currently known whether JN.1 infection produces different symptoms
from other variants. In general, symptoms of COVID-19 tend to be
similar across variants. The types of symptoms and how severe they are
usually depend more on a person's immunity and overall health rather
than which variant causes the infection"
(https://www.cdc.gov/respiratory-viruses/whats-new/SARS-CoV-2-variant-JN.1.=
html).
- Mod.PKB

ProMED map Bangladesh:
<https://promedmail.org/promed-post?place=3D8714329,153>]

[See Also:
COVID-19 update (06): India, decrease in cases
http://promedmail.org/post/20240117.8714284
COVID-19 update (05): Pakistan, JN.1, variant of interest
http://promedmail.org/post/20240111.8714166
COVID-19 update (04): selected locations, JN.1 virology, severity,
omicron BA.4.1 in dogs http://promedmail.org/post/20240111.8714155
COVID-19 update (03): Israel, JN.1, new variant
http://promedmail.org/post/20240104.8714055
COVID-19 update (02): India
http://promedmail.org/post/20240103.8714052
COVID-19 update (01): Cambodia, new JN.1 variant detection
http://promedmail.org/post/20240101.8714020
2023
----
COVID-19 update (39): Saudi Arabia, JN.1 variant, MOH
http://promedmail.org/post/20231222.8713858
COVID-19 update (38): WHO classifies JN.1 coronavirus strain as
'variant of interest' http://promedmail.org/post/20231220.8713808
COVID-19 update (37): vaccine comp., selected regions, circ. variants,
research http://promedmail.org/post/20231219.8713789
COVID-19 update (36): selected countries/regions, vaccines
http://promedmail.org/post/20231212.8713666
COVID-19 update (35): Singapore, increase
http://promedmail.org/post/20231209.8713618
COVID-19 update (34): selected country/region updates, variants, WHO
http://promedmail.org/post/20231130.8713398
COVID-19 update (33): country updates, vaccines, vaccine refusal, WHO
update http://promedmail.org/post/20231105.8713000
COVID-19 update (32): updates, variants, vaccines, antivirals,
scientific literature http://promedmail.org/post/20231026.8712809
COVID-19 update (31): BA.2.86 & EG.5, selected regions, vaccines, WHO,
global http://promedmail.org/post/20231009.8712522
COVID-19 update (30): omicron EG.5.1, updates, WHO, global
http://promedmail.org/post/20230815.8711701
COVID-19 update (29): updates, wastewater surveillance, transmission,
WHO, global http://promedmail.org/post/20230802.8711526
COVID-19 update (28): superspread, masks, vaccination, WHO, global
http://promedmail.org/post/20230724.8711339
COVID-19 update (27): vaccination, test kit distribution, sequelae,
WHO, global http://promedmail.org/post/20230717.8711208
COVID-19 update (26): animal, North America, wild deer as reservoirs
http://promedmail.org/post/20230713.8711124
COVID-19 update (25): vaccines, liver disease, sequelae, WHO, global
http://promedmail.org/post/20230713.8711095
COVID-19 update (24): long-term effects, EU.1.1, wild bat, WHO, global
http://promedmail.org/post/20230704.8710946
COVID-19 update (23): EU transition plan, viral emission, vacc
hesitancy, GBS, WHO http://promedmail.org/post/20230619.8710662
COVID-19 update (22): trends, immunity, children, metformin, WHO
http://promedmail.org/post/20230612.8710546
COVID-19 update (21): countries, life expectancy, long COVID,
research, WHO, global http://promedmail.org/post/20230605.8710423
COVID-19 update (20): countries, Paxlovid, vaccine, WHO
http://promedmail.org/post/20230530.8710317
COVID-19 update (19): countries, vaccine composition, XBB1.16, WHO,
global http://promedmail.org/post/20230522.8710178
COVID-19 update (18): country/regional, vaccine policies, vaccination,
WHO, global http://promedmail.org/post/20230516.8710088
COVID-19 update (17): WHO, USA, India, China, XBB.1.16, research,
global http://promedmail.org/post/20230508.8709926
COVID-19 update (16): XBB.1.16, reinfections, microglia, sequelae,
WHO, global http://promedmail.org/post/20230502.8709789
COVID-19 update (15): India, XBB.1.16, fetal brain damage, HCW, global
http://promedmail.org/post/20230417.8709526
COVID-19 update (14): countries, vaccines, XBB.1.16, long COVID, WHO
http://promedmail.org/post/20230407.8709377
COVID-19 update (13): India, surveillance, HCW, rats, infant
hospitalizations, WHO, global
http://promedmail.org/post/20230329.8709196
COVID-19 update (12): countries, variants, susceptibility, vaccines,
WHO, global http://promedmail.org/post/20230321.8709066
COVID-19 update (11): country responses, complications, treatment,
WHO, global http://promedmail.org/post/20230312.8708900
COVID-19 update (10): Hong Kong, XBB.1.5, Iran, UAE, bivalent vacc
http://promedmail.org/post/20230308.8708776
COVID-19 update (09): XBB.1.5, vaccine, WHO
http://promedmail.org/post/20230228.8708641
COVID-19 update (08): countries, immunity, vaccines, treatment, masks,
WHO, global http://promedmail.org/post/20230219.8708482
COVID-19 update (07): countries, molnupiravir, vaccines, PACS,
cockroach, WHO http://promedmail.org/post/20230212.8708331
COVID-19 update (06): China, demographics, symptoms, PACS, WHO
http://promedmail.org/post/20230204.8708165
COVID-19 update (05): PHEIC continues, WHO
http://promedmail.org/post/20230130.8708059
COVID-19 update (04): PHEIC, China, susp outbreaks, responses,
vaccines, global http://promedmail.org/post/20230130.8708043
COVID-19 update (03): China, guidelines, vacc, immunity, sequelae, WHO
http://promedmail.org/post/20230122.8707910
COVID-19 update (02): China, XBB.1.5, Hong Kong, mAb, pathogenesis,
WHO, global http://promedmail.org/post/20230115.8707786
COVID-19 update (01): China, Hong Kong, XBB.1.5, PAHO, treatment,
testing, WHO http://promedmail.org/post/20230107.8707667
2022
----
COVID-19 update (193): surge, travel restrictions, screening,
treatment, WHO http://promedmail.org/post/20221230.8707528
COVID-19 update (191): omicron BF.7, bivalent vaccines, China, WHO,
global http://promedmail.org/post/20221224.8707437
COVID-19 update (190): China, Australia, vaccines, sequelae, WHO,
global http://promedmail.org/post/20221219.8707306
COVID-19 update (189): mortality, mAb, intranasal vacc, NPIs,
sequelae, WHO, global http://promedmail.org/post/20221209.8707146
COVID-19 update (188): China, omicron BA.2.76, outdoor transmission
http://promedmail.org/post/20221130.8706983
COVID-19 update (187): boosters, omicron BQ.1.1, Asia, Australia, WHO,
global http://promedmail.org/post/20221129.8706920
COVID-19 update (185): chr. COVID, bladder, recovery, renal, deaths,
WHO, global http://promedmail.org/post/20221111.8706665
COVID-19 update (184): vaccination response, disparity, WHO, global
http://promedmail.org/post/20221104.8706549
COVID-19 update (183): cardiac events, exercise, US deaths, boosters,
WHO, global http://promedmail.org/post/20221028.8706414
COVID-19 update (182): frontline workers, life expectancy,
subvariants, WHO, global http://promedmail.org/post/20221021.8706286
COVID-19 update (181): Africa vacc hesitancy, pre-eclampsia, boosters,
nasal vacc, WHO, global http://promedmail.org/post/20221014.8706143
COVID-19 update (180): long COVID, neuropsy. illness, Paxlovid,
subvariants, WHO http://promedmail.org/post/20221007.8706007
COVID-19 update (170): case severity, boosters, physical activity,
WHO, global http://promedmail.org/post/20220825.8705236
COVID-19 update (160): vaccine rollout disparities, smell & taste,
WHO, global http://promedmail.org/post/20220731.8704776
COVID-19 update (150): France, omicron 2nd gen variant, paxlovid, WHO,
global http://promedmail.org/post/20220705.8704255
COVID-19 update (140): Thailand, human to cat to human transmission
http://promedmail.org/post/20220612.8703819
COVID-19 update (130): surveill., cardiac eff., long COVID subtypes,
WHO, global http://promedmail.org/post/20220601.8703606
COVID-19 update (120): N Korea, pandemic exit, youth vaccine, US
deaths, WHO http://promedmail.org/post/20220518.8703327
COVID-19 update (110): mutations, mental health, China, S Africa,
Paxlovid, WHO http://promedmail.org/post/20220505.8703018
COVID-19 update (100): vacc. intervals, deaths, long COVID,
subvariants, global http://promedmail.org/post/20220420.8702717
COVID-19 update (90): strategy, 2nd booster, WHO
http://promedmail.org/post/20220407.8702454
COVID-19 update (80): animal, USA, deer, transmission
http://promedmail.org/post/20220325.8702212
COVID-19 update (70): case count, UK, BA.2, USA, WHO, global
http://promedmail.org/post/20220312.8701940
COVID-19 update (60): animal, China, origin, research
http://promedmail.org/post/20220227.8701690
COVID-19 update (50): Hong Kong, estrogen risk, maternal vaccine
benefits, WHO http://promedmail.org/post/20220217.8701501
COVID-19 update (40): Denmark, rosemary, pregnancy, stroke, WHO
http://promedmail.org/post/20220205.8701276
COVID-19 update (30): variants in immuno-comp., stability, endemic,
WHO http://promedmail.org/post/20220126.8701074
COVID-19 update (20): Africa vacc., Taiwan, waning immunity,
persistence, global http://promedmail.org/post/20220117.8700915
COVID-19 update (10): animal, omicron origin statement, OIE
http://promedmail.org/post/20220110.8700763
COVID-19 update (01): omicron severity & changes, Germany, T-cell
reactivity http://promedmail.org/post/20220101.8700616]
.................................................pkb/rd/pkb/tw/jh
*##########################################################*
************************************************************
ProMED makes every effort to verify the reports that are posted, but the ac=
curacy
and completeness of the information, and of any statements or opinions base=
d
thereon, are not guaranteed. The reader assumes all risks in using informat=
ion
posted or archived by ProMED. ISID and its associated service providers sha=
ll not
be held responsible for errors or omissions or held liable for any damages =
incurred
as a result of use or reliance upon posted or archived material.
************************************************************
Donate to ProMED. Details available at: https://isid.networkforgood.com/pro=
jects/79924-invest-in-the-mission.
************************************************************
Visit ProMED's website at https://www.promedmail.org/.
Submit all items for posting via the ProMED website at https://promedmail.o=
rg/submitinfo/.
If you have any questions or need support, please contact us via the ProMED=
 website at  https://promedmail.org/support/.
You may subscribe/unsubscribe at  https://isid.org/promedmail-subscribe/.
Unsubscribe Preferences ( https://u19268662.ct.sendgrid.net/asm/?user_id=3D=
19268662&data=3D9UV2Bu4AseCIw-SEuufN8ONLHhCGVwW1wgiZL17pNcBoMDAwdTAwMDL8GrV=
po4atKQoOfr8kLDHMOZCMnbt5o4iwngJi3ptu_hcswEzm92vIqSnBIgUzb9TO_HQyBgN_8Ln31I=
n1Dhh1g0GkK4S0f4hQf6kulzHDyslQ5GM6D9gf-f3wBJZxBWKZL5-WHAj9_myx2-CA48SyRCX6h=
vMdeAhHvCGykjRF_8CYg2pIYfMkW8Vr-JMiIgh1w9uZd-wYX5KUwqhPTrrMcfajDThSv2n97QbS=
2o0f0xE3yUFM7EEk2_UInVpq7D9BH_cvz6OJAdFRG4KGCB4OA_yB8UNgWZcOrTRGWLnY1doYW3d=
9tXiNisrKk5sxXCjjZSptSU0qdW57GOeY6Yvs7nho91WtKJ1SjM3A0lkcNG3_ytty6N5vI441gM=
8ml023Wa-VvOS7B6vHte9SJw3RRshE1FIN5sCXd2c-HCw3sb-BxU457JBx-pp1jvDNQgiV3Xs2z=
CiFGlma96ch_pmYZzsPdUhw0uifKTFzKtGFAzpC2q7n1WTazyW7LpRQUdoZMgoApNhWxgTodjM8=
gJPvkpu1tsmL6ZNhin6wzYPCnSTw1VRdKrEUdSM8-9DPKYsBSjEwLp1H9WfHL9B_jaX7NAioYp2=
UXZzIiBpnNLfslbbMxh6BisI1aWvNxrmhl4QKIXBY5fA9vZ42_e_-8RG_Mzzg_ICYmJmDozvtN9=
CYY6VX3yYkGTdG6EiInsQZj6K95PKfcLxjANcmmS8B02WNdKZbykOJXl076g1IxkGeZhWY_bnY9=
2ThkSupc6v4VNdsbXVS3ZdttP61JGJjdxSzqplYVqsf88RgIw7mh8A2bC2VDWYQveqBRj3wly3a=
g7a9uhazf7S7NBqwjGzoCvLKRxl_vBMM5drHmD-DX4BgufdN4DYV3fnt2iS9XRXw-ymZ89vZtNZ=
aEEZ43FyW2hQSTViD5V3kM2-szcebHSDCYj0yin38mHxZg5VimOTXnvq0KvKZKODLcNW3AUkPzO=
23iqQ2FWuWLHN_rirxam7MJriFcwjuJyO-4A15JsOJmPIcWots5WF7w2C10j-UCGImdxej5RnwT=
pYwUTkUiH1k9NtLnzFJlYf7Pj9xXEiXJigUXesdw5dhaahpKGc2OJaQUAj-wNOztiHc9A8NvzY_=
Qs9RFIZMXKsLpFkMfjRJBxk9ZwqEBENGaxHyQwipZUVsshHR7ZQhwv7UJYpe-1Q7 )
############################################################
############################################################

--4e9324041eb89adb31d09602fbe3252c288b88fbd9a6defb07d4bdf3efb3
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset=us-ascii
Mime-Version: 1.0

<!DOCTYPE HTML>
<html>
<head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3DUTF-8" />
</head>
<body>CORONAVIRUS DISEASE 2019 UPDATE (07): BANGLADESH, JN.1, VARIANT OF<br=
>INTEREST<br>**************************************************************=
*************<br>A ProMED-mail post<br><a href=3D"https://u19268662.ct.send=
grid.net/ss/c/wscE2ng5fl6JrPIt48tisIijpefK5PNjW-mL-YZGnfgDOxU1G3gjwnPSi2Tfv=
3HA/435/6ptB7SslTmybwMyA0sYaRg/h0/-bJYWQ1qdPpLXe5kUyHZA9Rv3Pg5Y9Oy7od5lD54s=
rc">http://www.promedmail.org</a><br>ProMED-mail is a program of the<br>Int=
ernational Society for Infectious Diseases<br><a href=3D"https://u19268662.=
ct.sendgrid.net/ss/c/wscE2ng5fl6JrPIt48tisCT5tpD4Upm3qyMCbcYSQvc/435/6ptB7S=
slTmybwMyA0sYaRg/h1/PiBxeKBX1WyW6HVHUOKPCZTZac_CBsHZgYhTD00fBBs">http://www=
.isid.org</a><br><br>Date: Thu 18 Jan 2024=0D<br>Source: The Daily Star [ed=
ited]=0D<br><a href=3D"https://u19268662.ct.sendgrid.net/ss/c/TLh_csrC34X_i=
XpbYoMamyli1w1nJ_SajuXWLfn9xfVqgf6oTJVf4RDxFsebB5wMGPxtxeKaYWOOllllZCpJrzpf=
uAvtozNacxcxL_6VWw06f6migtOFg-k8_VZuHXZ_PeIZycp8S1BBx6hFJl-CUxcIGqctzqgFee-=
Pezh5d3w/435/6ptB7SslTmybwMyA0sYaRg/h2/RvHfm0qMZlW43hGex7BWZgtIccJy9rISCc45=
iIjtqCo">https://www.thedailystar.net/health/disease/news/bangladesh-report=
s-first-case-covid-19-sub-variant-jn1-3522486</a>=0D<br>=0D<br>=0D<br>Bangl=
adesh has reported its 1st case of COVID-19 sub-variant JN.1,<br>Institute =
of Epidemiology, Disease Control and Research (IEDCR) said<br>today [18 Jan=
 2024].=0D<br>=0D<br>This variant has been detected from 5 individuals, but=
 they don't have<br>any travel history, Professor Tahmina Shireen, director=
 of IEDCR, told<br>The Daily Star.=0D<br>=0D<br>She said, "Omicron's sub-va=
riant JN.1 has been identified in 5 samples<br>testing samples of coronavir=
us patients from Dhaka and from outside<br>Dhaka."=0D<br>=0D<br>--=0D<br>Co=
mmunicated by:=0D<br>ProMED=0D<br>via=0D<br>ProMED-SoAs<br><br>[As indicate=
d in the news report above, the more infectious JN.1<br>sub-variant of the =
omicron variant has been detected in 5 COVID-19<br>cases in Bangladesh. Wit=
h this confirmation, Bangladesh has become the<br>3rd country in South Asia=
, after India and Pakistan, reporting the<br>presence of this sub-variant.=0D=
<br>=0D<br>Recently, a slight up-trend of the COVID-19 cases is being repor=
ted in<br>Bangladesh<br>(<a href=3D"https://u19268662.ct.sendgrid.net/ss/c/=
TLh_csrC34X_iXpbYoMamyli1w1nJ_SajuXWLfn9xfVqgf6oTJVf4RDxFsebB5wMsMcWXLtHQ-E=
pzg8fDwvN5WNc1ilKV1KwTI6DQE97KVGW9oLB_a1QJaYKtIsODd7XhhW5tLbI9F2onNX-5KFcgm=
9Ja5cOE220yiXelLgbsa0/435/6ptB7SslTmybwMyA0sYaRg/h3/_TrobNgQPgEzbN_-D3BgtzR=
-uhT-2rPPukSnPLcSsFg">https://www.thedailystar.net/health/disease/coronavir=
us/news/covid-positivity-rate-rises-upto-45pc-3510936</a>).<br>Around 5 wee=
ks back, the start of a similar up-rise trend of daily<br>cases had cautiou=
sly been observed across India, suspected to have<br>been attributed to the=
 spread of the sub-variant JN.1. The daily<br>reported cases are now decrea=
sing again in the country (see archive<br>no. http://promedmail.org/post/20=
240117.8714266). Anyway, the spread<br>of the sub-variant in Bangladesh sho=
uld be closely monitored until the<br>recently noticed temporal surge dies =
completely.=0D<br>=0D<br>Of note, "JN.1 is closely related to the variant B=
A.2.86.... It is not<br>currently known whether JN.1 infection produces dif=
ferent symptoms<br>from other variants. In general, symptoms of COVID-19 te=
nd to be<br>similar across variants. The types of symptoms and how severe t=
hey are<br>usually depend more on a person's immunity and overall health ra=
ther<br>than which variant causes the infection"<br>(https://www.cdc.gov/re=
spiratory-viruses/whats-new/SARS-CoV-2-variant-JN.1.html).<br>- Mod.PKB=0D<=
br>=0D<br>ProMED map Bangladesh:<br><a href=3D"https://u19268662.ct.sendgri=
d.net/ss/c/sSnCkKCWBvais3EuVAOvgy2WOIX7pp1nXnn4AbwuQ3Z6WbkfhqXYXU-aTMPJ8yTh=
VrASP5IqDH3lPXAxy_QFGw/435/6ptB7SslTmybwMyA0sYaRg/h4/_8f6_-lJ8sXzH6pP44MGyx=
D4brN32pwSKvSOg1jBK_k">https://promedmail.org/promed-post?place=3D8714329,1=
53</a>]<br><br>[See Also:<br>COVID-19 update (06): India, decrease in cases=
<br>http://promedmail.org/post/20240117.8714284=0D<br>COVID-19 update (05):=
 Pakistan, JN.1, variant of interest<br>http://promedmail.org/post/20240111=
.8714166=0D<br>COVID-19 update (04): selected locations, JN.1 virology, sev=
erity,<br>omicron BA.4.1 in dogs http://promedmail.org/post/20240111.871415=
5=0D<br>COVID-19 update (03): Israel, JN.1, new variant<br>http://promedmai=
l.org/post/20240104.8714055=0D<br>COVID-19 update (02): India<br>http://pro=
medmail.org/post/20240103.8714052=0D<br>COVID-19 update (01): Cambodia, new=
 JN.1 variant detection<br>http://promedmail.org/post/20240101.8714020=0D<b=
r>2023=0D<br>----=0D<br>COVID-19 update (39): Saudi Arabia, JN.1 variant, M=
OH<br>http://promedmail.org/post/20231222.8713858=0D<br>COVID-19 update (38=
): WHO classifies JN.1 coronavirus strain as<br>'variant of interest' http:=
//promedmail.org/post/20231220.8713808=0D<br>COVID-19 update (37): vaccine =
comp., selected regions, circ. variants,<br>research http://promedmail.org/=
post/20231219.8713789=0D<br>COVID-19 update (36): selected countries/region=
s, vaccines<br>http://promedmail.org/post/20231212.8713666=0D<br>COVID-19 u=
pdate (35): Singapore, increase<br>http://promedmail.org/post/20231209.8713=
618=0D<br>COVID-19 update (34): selected country/region updates, variants, =
WHO<br>http://promedmail.org/post/20231130.8713398=0D<br>COVID-19 update (3=
3): country updates, vaccines, vaccine refusal, WHO<br>update http://promed=
mail.org/post/20231105.8713000=0D<br>COVID-19 update (32): updates, variant=
s, vaccines, antivirals,<br>scientific literature http://promedmail.org/pos=
t/20231026.8712809=0D<br>COVID-19 update (31): BA.2.86 & EG.5, selected reg=
ions, vaccines, WHO,<br>global http://promedmail.org/post/20231009.8712522=0D=
<br>COVID-19 update (30): omicron EG.5.1, updates, WHO, global<br>http://pr=
omedmail.org/post/20230815.8711701=0D<br>COVID-19 update (29): updates, was=
tewater surveillance, transmission,<br>WHO, global http://promedmail.org/po=
st/20230802.8711526=0D<br>COVID-19 update (28): superspread, masks, vaccina=
tion, WHO, global<br>http://promedmail.org/post/20230724.8711339=0D<br>COVI=
D-19 update (27): vaccination, test kit distribution, sequelae,<br>WHO, glo=
bal http://promedmail.org/post/20230717.8711208=0D<br>COVID-19 update (26):=
 animal, North America, wild deer as reservoirs<br>http://promedmail.org/po=
st/20230713.8711124=0D<br>COVID-19 update (25): vaccines, liver disease, se=
quelae, WHO, global<br>http://promedmail.org/post/20230713.8711095=0D<br>CO=
VID-19 update (24): long-term effects, EU.1.1, wild bat, WHO, global<br>htt=
p://promedmail.org/post/20230704.8710946=0D<br>COVID-19 update (23): EU tra=
nsition plan, viral emission, vacc<br>hesitancy, GBS, WHO http://promedmail=
.org/post/20230619.8710662=0D<br>COVID-19 update (22): trends, immunity, ch=
ildren, metformin, WHO<br>http://promedmail.org/post/20230612.8710546=0D<br=
>COVID-19 update (21): countries, life expectancy, long COVID,<br>research,=
 WHO, global http://promedmail.org/post/20230605.8710423=0D<br>COVID-19 upd=
ate (20): countries, Paxlovid, vaccine, WHO<br>http://promedmail.org/post/2=
0230530.8710317=0D<br>COVID-19 update (19): countries, vaccine composition,=
 XBB1.16, WHO,<br>global http://promedmail.org/post/20230522.8710178=0D<br>=
COVID-19 update (18): country/regional, vaccine policies, vaccination,<br>W=
HO, global http://promedmail.org/post/20230516.8710088=0D<br>COVID-19 updat=
e (17): WHO, USA, India, China, XBB.1.16, research,<br>global http://promed=
mail.org/post/20230508.8709926=0D<br>COVID-19 update (16): XBB.1.16, reinfe=
ctions, microglia, sequelae,<br>WHO, global http://promedmail.org/post/2023=
0502.8709789=0D<br>COVID-19 update (15): India, XBB.1.16, fetal brain damag=
e, HCW, global<br>http://promedmail.org/post/20230417.8709526=0D<br>COVID-1=
9 update (14): countries, vaccines, XBB.1.16, long COVID, WHO<br>http://pro=
medmail.org/post/20230407.8709377=0D<br>COVID-19 update (13): India, survei=
llance, HCW, rats, infant<br>hospitalizations, WHO, global<br>http://promed=
mail.org/post/20230329.8709196=0D<br>COVID-19 update (12): countries, varia=
nts, susceptibility, vaccines,<br>WHO, global http://promedmail.org/post/20=
230321.8709066=0D<br>COVID-19 update (11): country responses, complications=
, treatment,<br>WHO, global http://promedmail.org/post/20230312.8708900=0D<=
br>COVID-19 update (10): Hong Kong, XBB.1.5, Iran, UAE, bivalent vacc<br>ht=
tp://promedmail.org/post/20230308.8708776=0D<br>COVID-19 update (09): XBB.1=
.5, vaccine, WHO<br>http://promedmail.org/post/20230228.8708641=0D<br>COVID=
-19 update (08): countries, immunity, vaccines, treatment, masks,<br>WHO, g=
lobal http://promedmail.org/post/20230219.8708482=0D<br>COVID-19 update (07=
): countries, molnupiravir, vaccines, PACS,<br>cockroach, WHO http://promed=
mail.org/post/20230212.8708331=0D<br>COVID-19 update (06): China, demograph=
ics, symptoms, PACS, WHO<br>http://promedmail.org/post/20230204.8708165=0D<=
br>COVID-19 update (05): PHEIC continues, WHO<br>http://promedmail.org/post=
/20230130.8708059=0D<br>COVID-19 update (04): PHEIC, China, susp outbreaks,=
 responses,<br>vaccines, global http://promedmail.org/post/20230130.8708043=0D=
<br>COVID-19 update (03): China, guidelines, vacc, immunity, sequelae, WHO<=
br>http://promedmail.org/post/20230122.8707910=0D<br>COVID-19 update (02): =
China, XBB.1.5, Hong Kong, mAb, pathogenesis,<br>WHO, global http://promedm=
ail.org/post/20230115.8707786=0D<br>COVID-19 update (01): China, Hong Kong,=
 XBB.1.5, PAHO, treatment,<br>testing, WHO http://promedmail.org/post/20230=
107.8707667=0D<br>2022=0D<br>----=0D<br>COVID-19 update (193): surge, trave=
l restrictions, screening,<br>treatment, WHO http://promedmail.org/post/202=
21230.8707528=0D<br>COVID-19 update (191): omicron BF.7, bivalent vaccines,=
 China, WHO,<br>global http://promedmail.org/post/20221224.8707437=0D<br>CO=
VID-19 update (190): China, Australia, vaccines, sequelae, WHO,<br>global h=
ttp://promedmail.org/post/20221219.8707306=0D<br>COVID-19 update (189): mor=
tality, mAb, intranasal vacc, NPIs,<br>sequelae, WHO, global http://promedm=
ail.org/post/20221209.8707146=0D<br>COVID-19 update (188): China, omicron B=
A.2.76, outdoor transmission<br>http://promedmail.org/post/20221130.8706983=0D=
<br>COVID-19 update (187): boosters, omicron BQ.1.1, Asia, Australia, WHO,<=
br>global http://promedmail.org/post/20221129.8706920=0D<br>COVID-19 update=
 (185): chr. COVID, bladder, recovery, renal, deaths,<br>WHO, global http:/=
/promedmail.org/post/20221111.8706665=0D<br>COVID-19 update (184): vaccinat=
ion response, disparity, WHO, global<br>http://promedmail.org/post/20221104=
.8706549=0D<br>COVID-19 update (183): cardiac events, exercise, US deaths, =
boosters,<br>WHO, global http://promedmail.org/post/20221028.8706414=0D<br>=
COVID-19 update (182): frontline workers, life expectancy,<br>subvariants, =
WHO, global http://promedmail.org/post/20221021.8706286=0D<br>COVID-19 upda=
te (181): Africa vacc hesitancy, pre-eclampsia, boosters,<br>nasal vacc, WH=
O, global http://promedmail.org/post/20221014.8706143=0D<br>COVID-19 update=
 (180): long COVID, neuropsy. illness, Paxlovid,<br>subvariants, WHO http:/=
/promedmail.org/post/20221007.8706007=0D<br>COVID-19 update (170): case sev=
erity, boosters, physical activity,<br>WHO, global http://promedmail.org/po=
st/20220825.8705236=0D<br>COVID-19 update (160): vaccine rollout disparitie=
s, smell & taste,<br>WHO, global http://promedmail.org/post/20220731.870477=
6=0D<br>COVID-19 update (150): France, omicron 2nd gen variant, paxlovid, W=
HO,<br>global http://promedmail.org/post/20220705.8704255=0D<br>COVID-19 up=
date (140): Thailand, human to cat to human transmission<br>http://promedma=
il.org/post/20220612.8703819=0D<br>COVID-19 update (130): surveill., cardia=
c eff., long COVID subtypes,<br>WHO, global http://promedmail.org/post/2022=
0601.8703606=0D<br>COVID-19 update (120): N Korea, pandemic exit, youth vac=
cine, US<br>deaths, WHO http://promedmail.org/post/20220518.8703327=0D<br>C=
OVID-19 update (110): mutations, mental health, China, S Africa,<br>Paxlovi=
d, WHO http://promedmail.org/post/20220505.8703018=0D<br>COVID-19 update (1=
00): vacc. intervals, deaths, long COVID,<br>subvariants, global http://pro=
medmail.org/post/20220420.8702717=0D<br>COVID-19 update (90): strategy, 2nd=
 booster, WHO<br>http://promedmail.org/post/20220407.8702454=0D<br>COVID-19=
 update (80): animal, USA, deer, transmission<br>http://promedmail.org/post=
/20220325.8702212=0D<br>COVID-19 update (70): case count, UK, BA.2, USA, WH=
O, global<br>http://promedmail.org/post/20220312.8701940=0D<br>COVID-19 upd=
ate (60): animal, China, origin, research<br>http://promedmail.org/post/202=
20227.8701690=0D<br>COVID-19 update (50): Hong Kong, estrogen risk, materna=
l vaccine<br>benefits, WHO http://promedmail.org/post/20220217.8701501=0D<b=
r>COVID-19 update (40): Denmark, rosemary, pregnancy, stroke, WHO<br>http:/=
/promedmail.org/post/20220205.8701276=0D<br>COVID-19 update (30): variants =
in immuno-comp., stability, endemic,<br>WHO http://promedmail.org/post/2022=
0126.8701074=0D<br>COVID-19 update (20): Africa vacc., Taiwan, waning immun=
ity,<br>persistence, global http://promedmail.org/post/20220117.8700915=0D<=
br>COVID-19 update (10): animal, omicron origin statement, OIE<br>http://pr=
omedmail.org/post/20220110.8700763=0D<br>COVID-19 update (01): omicron seve=
rity & changes, Germany, T-cell<br>reactivity http://promedmail.org/post/20=
220101.8700616]<br>.................................................pkb/rd/=
pkb/tw/jh<br></body>
</html><!DOCTYPE HTML>
<html>
<head>
<meta http-equiv=3D"Content-Type" content=3D"text/html; charset=3DUTF-8" />
</head>
<body>*##########################################################*<br>*****=
*******************************************************<br>ProMED makes eve=
ry effort to verify the reports that are posted, but the accuracy<br>and co=
mpleteness of the information, and of any statements or opinions based<br>t=
hereon, are not guaranteed. The reader assumes all risks in using informati=
on<br>posted or archived by ProMED. ISID and its associated service provide=
rs shall not<br>be held responsible for errors or omissions or held liable =
for any damages incurred<br>as a result of use or reliance upon posted or a=
rchived material.<br>******************************************************=
******<br>Donate to ProMED. Details available at: https://isid.networkforgo=
od.com/projects/79924-invest-in-the-mission.<br>***************************=
*********************************<br>Visit ProMED's website at https://www.=
promedmail.org/.<br>Submit all items for posting via the ProMED website at =
https://promedmail.org/submitinfo/.<br>If you have any questions or need su=
pport, please contact us via the ProMED website at  https://promedmail.org/=
support/.<br>You may subscribe/unsubscribe at  https://isid.org/promedmail-=
subscribe/.<br><div><a href=3D"https://u19268662.ct.sendgrid.net/asm/?user_=
id=3D19268662&amp;data=3D9UV2Bu4AseCIw-SEuufN8ONLHhCGVwW1wgiZL17pNcBoMDAwdT=
AwMDL8GrVpo4atKQoOfr8kLDHMOZCMnbt5o4iwngJi3ptu_hcswEzm92vIqSnBIgUzb9TO_HQyB=
gN_8Ln31In1Dhh1g0GkK4S0f4hQf6kulzHDyslQ5GM6D9gf-f3wBJZxBWKZL5-WHAj9_myx2-CA=
48SyRCX6hvMdeAhHvCGykjRF_8CYg2pIYfMkW8Vr-JMiIgh1w9uZd-wYX5KUwqhPTrrMcfajDTh=
Sv2n97QbS2o0f0xE3yUFM7EEk2_UInVpq7D9BH_cvz6OJAdFRG4KGCB4OA_yB8UNgWZcOrTRGWL=
nY1doYW3d9tXiNisrKk5sxXCjjZSptSU0qdW57GOeY6Yvs7nho91WtKJ1SjM3A0lkcNG3_ytty6=
N5vI441gM8ml023Wa-VvOS7B6vHte9SJw3RRshE1FIN5sCXd2c-HCw3sb-BxU457JBx-pp1jvDN=
QgiV3Xs2zCiFGlma96ch_pmYZzsPdUhw0uifKTFzKtGFAzpC2q7n1WTazyW7LpRQUdoZMgoApNh=
WxgTodjM8gJPvkpu1tsmL6ZNhin6wzYPCnSTw1VRdKrEUdSM8-9DPKYsBSjEwLp1H9WfHL9B_ja=
X7NAioYp2UXZzIiBpnNLfslbbMxh6BisI1aWvNxrmhl4QKIXBY5fA9vZ42_e_-8RG_Mzzg_ICYm=
JmDozvtN9CYY6VX3yYkGTdG6EiInsQZj6K95PKfcLxjANcmmS8B02WNdKZbykOJXl076g1IxkGe=
ZhWY_bnY92ThkSupc6v4VNdsbXVS3ZdttP61JGJjdxSzqplYVqsf88RgIw7mh8A2bC2VDWYQveq=
BRj3wly3ag7a9uhazf7S7NBqwjGzoCvLKRxl_vBMM5drHmD-DX4BgufdN4DYV3fnt2iS9XRXw-y=
mZ89vZtNZaEEZ43FyW2hQSTViD5V3kM2-szcebHSDCYj0yin38mHxZg5VimOTXnvq0KvKZKODLc=
NW3AUkPzO23iqQ2FWuWLHN_rirxam7MJriFcwjuJyO-4A15JsOJmPIcWots5WF7w2C10j-UCGIm=
dxej5RnwTpYwUTkUiH1k9NtLnzFJlYf7Pj9xXEiXJigUXesdw5dhaahpKGc2OJaQUAj-wNOztiH=
c9A8NvzY_Qs9RFIZMXKsLpFkMfjRJBxk9ZwqEBENGaxHyQwipZUVsshHR7ZQhwv7UJYpe-1Q7" =
target=3D"_blank" class=3D"Unsubscribe--unsubscribePreferences" style=3D"fo=
nt-family:sans-serif;text-decoration:none;">Unsubscribe Preferences</a></di=
v><br>############################################################<br>#####=
#######################################################<br><br><img src=3D"=
https://u19268662.ct.sendgrid.net/ss/o/LbtalBvHhFtzyiegKfBhew/435/6ptB7SslT=
mybwMyA0sYaRg/ho.gif" alt=3D"" width=3D"1" height=3D"1" border=3D"0" style=
=3D"height:1px !important;width:1px !important;border-width:0 !important;ma=
rgin-top:0 !important;margin-bottom:0 !important;margin-right:0 !important;=
margin-left:0 !important;padding-top:0 !important;padding-bottom:0 !importa=
nt;padding-right:0 !important;padding-left:0 !important;"/></body>
</html>
--4e9324041eb89adb31d09602fbe3252c288b88fbd9a6defb07d4bdf3efb3--
